EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Revisiting an old therapy for new, promising combinations: Biology and perspectives of lomustine in glioma treatment

Charlotte Bellamy iD, Cynthia Hajal, Keith L Ligon, Mehdi Touat iD

Neuro-Oncology · 01.12.2025 · 27 (12) · 3043-3057

DOI: 10.1093/neuonc/noaf192 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuro-Oncology, online erschienen am 13.08.2025. Verfasst von Charlotte Bellamy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Dana-Farber Cancer Institute, Boston, MA, USA. Hauptthemen laut MEDLINE: Lomustine, Glioma, Brain Neoplasms, Antineoplastic Agents, Alkylating. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: French Ministry of Education and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The alkylating agents temozolomide (TMZ) and lomustine (CCNU) are the most effective systemic agents for malignant gliomas. However, resistance—whether intrinsic or acquired—inevitably develops in all patients, and these tumors remain incurable. Although CCNU has demonstrated clinical benefit, its clinical use has been relatively limited due to a less favorable safety profile compared to TMZ. Recently, interest in CCNU and other nitrosoureas has been renewed in light of positive clinical trials in both adult and pediatric gliomas. Despite this renewed attention, critical questions remain unaddressed regarding the use of nitrosoureas. While resistance and response to temozolomide have been associated with the status of both MGMT and the mismatch repair DNA repair pathway, our understanding of the unique mechanisms of resistance to nitrosoureas beyond MGMT remains limited. Recent advances in molecular biology, preclinical models, and the use of longitudinal analyses of treated samples provide new insights, offering opportunities to refine clinical use and develop novel strategies. In this review, we explore the current role of nitrosoureas in glioma treatment, examine known and emerging mechanisms of sensitivity and resistance to these agents, and explore the potential for combination approaches to enhance their efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LomustineGliomaBrain NeoplasmsAntineoplastic Agents, AlkylatingAntineoplastic Combined Chemotherapy ProtocolsHumansDrug Resistance, NeoplasmAnimals

Stichwörter der Autor:innen

DNA damagebiomarkerschemotherapygliomaprecision medicineresistance

Substanzen

LomustineAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Department of Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Paris Brain Institute (ICM), Hôpital Pitié-Salpêtrière, Inserm U 1127, CNRS UMR 7225, Sorbonne Université, Paris, France.
  • Department of Bioengineering and Mechanobiology Institute, Northeastern University, Boston, MA, USA.
  • Department of Mechanical and Industrial Engineering, Northeastern University, Boston, MA, USA.
  • Broad Institute of Harvard and MIT, Cambridge, MA, USA.
  • Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.

ORCID-Profile: Charlotte Bellamy, Mehdi Touat

Förderung

  • French Ministry of Education and Research

Zitieren

APA

Bellamy, C., Hajal, C., Ligon, K. L., & Touat, M. (2025). Revisiting an old therapy for new, promising combinations: Biology and perspectives of lomustine in glioma treatment. Neuro-Oncology, 27(12), 3043-3057. https://doi.org/10.1093/neuonc/noaf192

Vancouver

Bellamy C, Hajal C, Ligon KL, Touat M. Revisiting an old therapy for new, promising combinations: Biology and perspectives of lomustine in glioma treatment. Neuro-Oncology. 2025;27(12):3043-3057. doi:10.1093/neuonc/noaf192

BibTeX
@article{Bellamy2025,
  author = {Bellamy, Charlotte and Hajal, Cynthia and Ligon, Keith L and Touat, Mehdi},
  title = {Revisiting an old therapy for new, promising combinations: Biology and perspectives of lomustine in glioma treatment},
  journal = {Neuro-Oncology},
  year = {2025},
  volume = {27},
  number = {12},
  pages = {3043--3057},
  doi = {10.1093/neuonc/noaf192}
}
Kostenlos starten →